INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
LY

Luo Yuling

Director, Chief Executive OfficerCIK 0002126941

EDGAR filingsOpen in network
Disclosed transactions29
Buys / sells0 / 0
Max Insider Score21
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
1.86M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Alamar Biosciences, Inc.Director, Chief Executive Officer · Apr 20, 2026
9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C
—
1.22M sh
Apr 20, 2026
Apr 20, 2026
traded Apr 20, 2026
+0d
SEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
1.22M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
1.22M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
266.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

21
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
1.39M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

17
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
364.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
1.86M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
1.03M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
37.1K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
37.1K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
266.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
25.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
24.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
24.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
20.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
20.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
27.7K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
1.03M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Grant or award
A—
341.2K sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
1.02M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
366.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
880.8K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
1.22M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
42.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Grant or award
A—
76.5K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
42.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
25.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
27.7K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence